The Mechanism by Which Flaxseed Oil Consumption Increases Bleeding Time in Patients with Type 2 Diabetes in Cape Breton, Nova Scotia, Canada is Independent of Lipoprotein(a) Concentration

Journal of Oleo Science

Volumn 54, Issue 12, 2005, Pages 617-625

  Barre, Douglas E ^a   Griscti, Odette ^a   Mizier Barre, Kazimiera A ^a   Hafez, Kevin ^a  

^a CAPE BRETON UNIVERSITY   (Canada)

Author keywords

bleeding time; flax oil; gender; lipoprotein (a); type 2 diabetes

Indexed keywords

EID: 85007459737     PISSN: 13458957     EISSN: 13473352     Source Type: Journal    
DOI: 10.5650/jos.54.617     Document Type: Article

References (45)

1. P. FERRONI, S. BASILI, A. FALCO and G. DAVI, Platelet Activation in Type 2 Diabetes Mellitus, J. Thromb. Haemost., Vol. 2, 1282-1291 (2004).
2. C. PACKARD and A. G. OLSSON, Management of Hyper-cholesterolaemia in the Patient with Diabetes, Int. J. Clin. Pract. Suppl., Vol. 130, 27-32 (2002).
3. R. P. C. RODGERS and J. LEVIN, A Critical Reappraisal of the Bleeding Time, Semin. Thromb. Haemostasis, Vol. 16, 1-20 (1990).
4. J. R. O'BRIEN, The Bleeding Time in Normal and Abnormal Subjects, J. Clin. Pathol., Vol. 4, 272-285 (1951).
5. J. SAGEL, J. A. COLWELL, L. CROOK and M. LAIMINS, Increased Platelet Aggregation in Early Diabetes Mellitus, Ann. Intern. Med., Vol. 82, 733-738 (1975).
6. S. MANDAL, R. SARODE, S. DASH and R. J. DASH, Hyperag-gregation of Platelets Detected by Whole Blood Platelet Aggre-gometry in Newly Diagnosed Noninsulin-Dependent Diabetes Mellitus, Am. J. Clin. Pathol., Vol. 100, 103-107 (1993).
7. L. HANSSON, A. ZANCHETTI, S. G. CARRUTHERS, B. DAHLOF, D. ELMFELDT, S. JULIUS, J. MENARD, K. H. RAHN, H. WEDEL and S. WESTERLING, Effects of Intensive Blood-Pressure Lowering and Low-Dose Aspirin in Patients with Hypertension, Principal Results of the Hypertension Optimal Treatment (HOT) Randomised Trial. HOT Study Group, Lancet, Vol. 351, 1755-1762 (1998).
8. J. A. COLWELL, Aspirin Therapy in Diabetes (Technical Review), Diabetes Care, Vol. 20, 1767-1771 (1997).
9. J. K. CHAN, B. E. MCDONALD, J. M. GERRARD, V. M. BRUCE, B. J. WEAVER and B. J. HOLUB, Effect of Dietary Alpha-Linolenic Acid and its Ratio to Linoleic Acid on Platelet and Plasma Fatty Acids and Thrombogenesis, Lipids, Vol. 28, 811-817 (1993).
10. D. S. KELLEY, G. J. NELSON, J. E. LOVE, L. B. BRANCH, P. C. TAYLOR, P. C. SCHMIDT, B. E. MACKEY and J. M. IACONO, Dietary Alpha-Linolenic Acid Alters Tissue Fatty Acid Composition, but not Blood Lipids, Lipoproteins or Coagulation Status in Humans, Lipids, Vol. 28, 533-537 (1993).
11. S. RENAUD, R. MORAZAIN, F. GODSEY, E. DUMONT, C. THEVENON, J. L. MARTIN and F. MENDY, Nutrients, Platelet Function and Composition in Nine Groups of French and British Farmers, Atherosclerosis, Vol. 60, 37-48 (1986).
12. S. RENAUD, F. GODSEY, E. DUMONT, C. THEVENON, E. ORTCHANIAN and J. L. MARTIN, Influence of Long-Term Diet Modification on Platelet Function and Composition in Moselle Farmers, Am. J. Clin. Nutr., Vol. 43, 136-150 (1986).
13. M. A. ALLMAN, M. M. PENA and D. PANG, Supplementation with Flaxseed Oil versus Sunflowerseed Oil in Healthy Young Men Consuming a Low Fat Diet, Effects on Platelet Composition and Function, Eur. J. Clin. Nutr., Vol. 49, 169-178 (1995).
14. A. P. SIMOPOULOS, Essential Fatty Acids in Health and Chronic Disease, Am. J. Clin. Nutr., Vol. 70, 560S-569S (1999).
15. A. P. SIMOPOULOS, Omega-3 Fatty Acids in Health and Disease and in Growth and Development, Am. J. Clin. Nutr., Vol. 54, 438-463 (1991).
16. B. J. HOLUB, Clinical Nutrition, 4. Omega-3 Fatty Acids in Cardiovascular Care, CMAJ., Vol. 166, 608-615 (2002).
17. E. A. EMKEN, R. O. ADLOF and R. M. GULLEY, Dietary Linoleic Acid Influences Desaturation and Acylation of Deuterium-Labeled Linoleic acids and Linolenic Acids in Young Adult Males, Biochem. Biophys Acta, Vol. 1213, 277-288 (1994).
18. M. HAMBERG, J. SVENSSON and B. SAMUELSSON, Thromboxanes, a New Group of Biologically Active Compounds Derived from Prostaglandin Endoperoxides, Proc. Natl. Acad. Sci. USA, Vol. 72, 2994-2998 (1975).
19. G. RAJTAR, C. CERLETTI, M. N. CASTAGNOLI, V. BERTELE and G. DE GAETANO, Prostaglandins and Human Platelet Aggregation. Implications for the Anti-Aggregating Activity of Thromboxane-Synthase Inhibitors, Biochem. Pharmacol., Vol. 34, 307-310 (1985).
20. D. D. LABUDOVIC, K. N. TOSESKA, S. B. ALABAKOVSKA and B. TODOROVA, Apoprotein(a) Phenotypes and Plasma Lipoprotein(a) Concentration in Patients with Diabetes Mellitus, Clin Biochem., Vol. 36, 545-551 (2003).
21. S. S. HABIB and M. ASLAM, Lipids and Lipoprotein(a) Concentrations in Pakistani Patients with Type 2 Diabetes Mellitus, Diabetes Obes. Metab., Vol. 6, 338-343 (2004).
22. R. CARMENA, P. DURIEZ and J. C. FRUCHART, Atherogenic Lipoprotein Particles in Atherosclerosis, Circulation, Vol. 109, III2-7 (2004).
23. J. C. FRUCHART, M. C. NIERMAN, E. S. STROES, J. J. KASTELEIN, P. DURIEZ, New Risk Factors for Atherosclerosis and Patient Risk Assessment, Circulation, Vol. 109, III15-9 (2004).
24. L. B. NIELSEN, Atherogenicity of Lipoprotein(a) and Oxidized Low Density Lipoprotein, Insight from in vivo Studies of Arterial Wall Influx, Degradation and Efflux, Atherosclerosis, Vol. 143, 229-243 (1999).
25. M. L. KOSCHINSKY, Lipoprotein(a) and the Link between Atherosclerosis and Thrombosis, Can. J. Cardiol., Vol. 22(suppl B), 37B-43B (2004).
26. D. L. EATON, G. M. FLESS, W. J. KOHR, J. W. MCLEAN, Q. T. XU, C. G. MILLER, R. M. LAWN and A. M. SCANU, Partial Amino Acid Sequence of Apolipoprotein(a) Shows that it is Homologous to Plasminogen, Proc. Natl. Acad. Sci. USA, Vol. 84, 3224-3228 (1987).
27. J. W. MCLEAN, J. E. TOMLINSON, W. J. KUANG, D. L. EATON, E. Y. CHEN, G. M. FLESS, A. M. SCANU and R. M. LAWN, cDNA Sequence of Apolipoprotein(a) is Homologous to Plasminogen, Nature, Vol. 330, 132-137 (1987).
28. V. J. MARDER and W. R. BELL, Fibrinolytic Therapy, in Haemostasis and Thrombosis. Basic Principles and Clinical Practice (R.W. COLMAN, J. HIRSH, V.J. MARDER, E.W. SALZMAN, ed.), 2nd edn, pp. 1393-1437 (1989).
29. J. L. MILLER, A. J. KATZ and M. B. FEINSTEIN, Plasmin Inhibition of Thrombin-induced Platelet Aggregation, Thromb. Diath. Haemorrh., Vol. 33, 286-309 (1975).
30. M. A. HANCOCK, M. B. BOFFA, S. M. MARCOVINA, M. E. NESHEIM and M. L. KOSCHINSKY, Inhibition of Plasminogen Activation by Lipoprotein(a), Critical Domains in Apolipopro-tein(a) and Mechanism of Inhibition on Fibrin and Degraded Fibrin Surfaces, J. Biol. Chem., Vol. 278, 23260-23269 (2003).
31. R. TESTA and S. M. MARCOVINA, The Rate of Plasmin Formation after in vitro Clotting in Inversely Related to Lipopro-tein(a) Plasma Levels, Intl. J. Lab. Clin. Res., Vol. 29, 128-132 (1999).
32. W. F. B. AKER Jr., Thrombolytic Therapy, Clin. Appl Thromb. Hemost., Vol. 8, 291-314 (2002).
33. V. J. MARDER and D. STEWART, Toward Safer Thrombolytic Therapy, Semin. Hematol., Vol. 39, 206-216 (2002).
34. 2 Production, Platelets, Vol. 9, 93-96 (1998).
35. D. BARRE, Human Lipoprotein (a)-induced Reduction of Platelet Aggregation is not Mediated by Apolipoprotein A's Lysine-Binding Regions, Front. BioSci., Vol. 8, s1226-s1228 (2003).
36. D. E. BARRE, Apolipoprotein (a) Mediates the Lipoprotein (a)-induced Biphasic Shift in Human Platelet Cyclic AMP, Thromb. Res., Vol. 112, 321-324 (2003).
37. D. E. BARRE, Apoprotein (A) Antagonises the GPIIB/IIIA Receptor on Collagen- and ADP-Stimulated Human Platelets, Front. BioSci., Vol. 9, 404-410 (2004).
38. D. E. BARRE, Human Lipoprotein (a) is an Antagonist of Fi-brinogen that Binds to the GPIIb (CD41) Protein on Agonist-Stimulated Human Platelets, J. Oleo Sci., Vol. 53, 305-308 (2004).
39. M. L. RAND, W. SANGRAR, M. A. HANCOCK, D. M. TAYLOR, S. M. MARCOVINA, M. A. PACKHAM and M. L. KOSCHINSKY, Apolipoprotein (a) Enhances Platelet Responses to the Thrombin Receptor-activating Peptide SFLLRN, Arte-rioscler. Thromb. Vasc. Biol., Vol. 18, 1393-1399 (1998).
40. C. MARTINEZ, J. RIVERA, S. LOYAU, J. CORRAL, R. GON-ZALEZ-CONEJERO, M. L. LOZANO, V. VICENTE and E. ANGLES-CANO, Binding of Recombinant Apolipoprotein(a) to Human Platelets and Effect on Platelet Aggregation, Thromb. Haemost., Vol. 85, 686-693 (2001).
41. E. MALLE, A. IBOVNIK, H. J. LEIS, G. M. KOSTNER, P. F. VERHALLEN and W. SATTLER, Lysine Modification of LDL or Lipoprotein(a) by 4-Hydroxynonenal or Malondialdehyde Decreases Platelet Serotonin Secretion without Affecting Platelet Aggregability and Eicosanoid Formation, Arterioscler. Thromb. Vasc. Biol., Vol. 15, 377-384 (1995).
42. C. H. MIELKE, M. M. KANESHIRO, I. A. MAHER, J. M. WEINER and S. I. RAPAPORT, The Standardized Normal Ivy Bleeding Time and its Prolongation by Aspirin, Blood, Vol. 34, 204-215 (1969).
43. P. GRESELE, G. GUGLIELMINI, M. DE ANGELIS, S. CIFER-RI, M. CIOFETTA, E. FALCINELLI, C. LALLI, G. CIABAT-TONI, G. DAVI, and G. B. BOLLI, Acute, Short-term Hyper-glycemia Enhances Shear Stress-induced Platelet Activation in Patients with Type II Diabetes Mellitus, J. Am. Coll. Cardiol., Vol. 41, 1013-1020 (2003).
44. A. NOTARBARTOLO, G. DAVI, M. AVERNA, C. M. BARBA-GALLO, A. GANCI, C. GIAMMARRESI, F. P. LA PLACA and C. PATRONO, Inhibition of Thromboxane Biosynthesis and Platelet Function by Simvastatin in Type IIa Hypercholes-terolemia, Arterioscler. Thromb. Vasc. Biol., Vol. 15, 247-251 (1995).
45. P. NEEDLEMAN, M. O. WHITAKER, A. WYCHE, K. WAT-TERS, H. SPRECHER and A. RAZ, Manipulation of Platelet Aggregation by Prostaglandins and their Fatty Acid Precursors, Pharmacological Basis for a Therapeutic Approach, Prostaglandins, Vol. 19, 165-181 (1980).